Curriculum
Module 11 · 45 min

GnRH Analogs, Somatostatin & Oncology Peptides

Leuprolide, octreotide, lanreotide, pasireotide — the established peptide oncology toolkit.

ClinicalAdvanced
Core topics

What's covered

Click any topic to expand a deeper drill-down with mechanism, key references, and a take-home summary.

Learning objectives

By the end of this module you will be able to

  • L01Explain the flare effect and how it's managed.
  • L02Match somatostatin analogs to their NET indications.
Expected takeaways

What you should walk away believing

Click any takeaway to open a full AI-generated lesson with mechanism, examples, evidence grading, counseling scripts, pearls, references, and a self-check.

Takeaway mastery
0 / 2 · 0%
A takeaway counts as mastered when you score ≥80% on its self-check.
Lesson · Core emphasis

What this means for you

Patient summary

These older peptide drugs are mainstays in prostate cancer, endometriosis, and rare hormone-secreting tumors.

Clinician summary

PRRT (177Lu-DOTATATE) extended PFS in midgut NETs (NETTER-1); now standard for SSTR-positive progressive disease.

Evidence-graded claims

What the data say

A
GnRH agonists are first-line for advanced prostate cancer ADT
Decades of guideline support.
A
PRRT extends PFS in midgut NETs
NETTER-1, NEJM 2017.
Quick check

Test yourself

Q1Why does leuprolide cause an initial 'flare'?
Flashcards · Spaced repetition

Lock it in — review what's due

Due1Total1
FrontNew
1 in queue
Pasireotide receptor profile vs octreotide?
Click to reveal answer
References · 2

Sources cited in this module

  1. [1]
    LUPRON DEPOT (leuprolide acetate) Prescribing Information
    FDA Label · 2014Regulatory · T1
  2. [2]
    Somatostatin analogs in the treatment of neuroendocrine tumors
    Stueven AK. et al. · International Journal of Molecular Sciences · 2019Review · T2
Browse full references library →
Finish →
Capstone project